Why the study?
Does a dual-marker strategy incorporating a natriuretic peptide and cTnT improve prediction of mortality in patients with acute heart failure?
Does a dual-marker strategy incorporating a natriuretic peptide and cTnT improve prediction of mortality in patients with acute heart failure?
A dual-marker strategy using both a natriuretic peptide and cTnT at presentation is superior to either marker alone for predicting short- and long-term mortality in acute heart failure.
No takes yet. Share an insight, caveat, or question.
Dual-marker elevation may aid mortality risk stratification in acute HF; hypothesis-generating and should not yet change practice.
Sakhuja et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: